Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
Fraker
D L
DL
Surgical Metabolism Section, National Cancer Institute, Bethesda, Maryland.
Alexander
H R
HR
D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D004354:Drug Screening Assays, Antitumor; D005121:Extremities / Q000098:blood supply; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy*; D008558:Melphalan / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000628:therapy; D012509:Sarcoma / Q000188:drug therapy / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000628:therapy; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000627:therapeutic use*
D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D008558:Melphalan